AI Research Insights

HPV is strongly linked to cervical and other cancers worldwide, highlighting the importance of vaccination, screening, and surveillance.

Cutaneous melanoma is an increasingly prevalent skin cancer with marked geographic variation, significant mortality burden, and preventable risk factors worldwide.

Lung cancer remains a leading global cause of death, with declining rates in some regions but rising cases, shifting histology, disparities, and prevention challenges.

Prostate cancer shows major global disparities: high-income regions overdetect indolent disease, while low-resource settings face late diagnosis, higher mortality, and survivorship burdens.

Colorectal cancer burden remains high worldwide, with regional disparities, rising early-onset cases, and prevention centered on risk reduction and screening.

HPV drives a major global cancer burden through persistent oncogenic infection, shaping epidemiology, prevention, screening, and treatment strategies.

Leukemia imposes a substantial global burden, with evolving mortality, survival, disability, and quality-of-life patterns across subtypes and populations.

This review summarizes global gastric cancer epidemiology, trends, subtype patterns, and prevention strategies, highlighting regional disparities and screening implications.

Global pancreatic cancer burden is rising; prevention, early detection, and targeted surveillance are key to improving outcomes and reducing mortality.

siRNA therapeutics have prompted specialized regulatory frameworks addressing their unique mechanisms, manufacturing, and safety, shaping clinical development, monitoring, and therapeutic use.

Accelerated oncology approvals speed access via surrogate endpoints, but withdrawal rates, delayed confirmatory trials, and expanding coordination expose evidentiary risks.

AAV shows greatest clinical value in selected indications requiring durable gene addition, but immunogenicity, dose burden, safety, and competing modalities constrain broader adoption.

AAV gene therapy shows strong progress and durable benefit, but toxicity, immunity, manufacturing, and access still limit broader clinical adoption.

CAR-T is innovating through multispecific designs and faster manufacturing, but durable commercial success still depends on scalability, safety, reimbursement, and differentiation.

MASH treatment is evolving beyond GLP-1–based therapy to include liver-targeted and metabolic agents with distinct efficacy, tolerability, and combination potential.

Landmark TIGIT studies revealed early promise but inconsistent phase 3 efficacy, manageable safety, emerging biomarker signals, and the need for biomarker-guided trials.

PD-1 therapies continue to evolve through regulatory milestones, biomarker-guided combinations, and novel bispecific strategies that increasingly define future clinical value.

Recent EGFR-targeted NSCLC dealmaking reflects surging China-origin innovation, milestone-heavy structures, and premium valuation for clinically differentiated assets.